Development of effective vaccines against pandemic influenza

Immunity

Volumn 24, Issue 1, 2006, Pages 5-9

  Subbarao, Kanta ^a   Murphy, Brian R ^a   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; VIRUS ANTIBODY; VIRUS PROTEIN;

CELLULAR IMMUNITY; EPIDEMIC; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; INFLUENZA; INFLUENZA VIRUS; MEDICAL TECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 30444444679     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immuni.2005.12.005     Document Type: Note

References (17)

1. P.C. Crawford, E.J. Dubovi, W.L. Castleman, I. Stephenson, E.P. Gibbs, L. Chen, C. Smith, R.C. Hill, P. Ferro, and J. Pompey Transmission of equine influenza virus to dogs Science 310 2005 482 485
2. M.D. de Jong, T.T. Tran, H.K. Truong, M.H. Vo, G.J. Smith, V.C. Nguyen, V.C. Bach, T.Q. Phan, Q.H. Do, and Y. Guan Oseltamivir resistance during treatment of influenza A (H5N1) infection N. Engl. J. Med. 353 2005 2667 2672
3. S.L. Epstein Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: An experiment of nature J. Infect. Dis. 193 2006 49 53
4. W.M. Fitch, R.M. Bush, C.A. Bender, and N.J. Cox Long term trends in the evolution of H(3) HA1 human influenza type A Proc. Natl. Acad. Sci. USA 94 1997 7712 7718
5. N. Hehme, H. Engelmann, W. Kunzel, E. Neumeier, and R. Sanger Pandemic preparedness: Lessons learnt from H2N2 and H9N2 candidate vaccines Med. Microbiol. Immunol. (Berl.) 191 2002 203 208
6. Q.M. Le, M. Kiso, K. Someya, Y.T. Sakai, T.H. Nguyen, K.H. Nguyen, N.D. Pham, H.H. Ngyen, S. Yamada, and Y. Muramoto Avian flu: Isolation of drug-resistant H5N1 virus Nature 437 2005 1108
7. C.J. Luke, and K. Subbarao Vaccines for pandemic influenza Emerg. Infect. Dis. 12 2006 66 72
8. B.R. Murphy, and R.M. Chanock Immunization against viral diseases D.M. Knipe Fields Virology 2001 Lippincott, Williams & Wilkins Philadelphia, PA 435 468
9. S. Neirynck, T. Deroo, X. Saelens, P. Vanlandschoot, W.M. Jou, and W. Fiers A universal influenza A vaccine based on the extracellular domain of the M2 protein Nat. Med. 5 1999 1157 1163
10. K.G. Nicholson, A.E. Colegate, A. Podda, I. Stephenson, J. Wood, E. Ypma, and M.C. Zambon Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza Lancet 357 2001 1937 1943
11. R.J. Russell, S.J. Gamblin, L.F. Haire, D.J. Stevens, B. Xiao, Y. Ha, and J.J. Skehel H1 and H7 influenza haemagglutinin structures extend a structural classification of haemagglutinin subtypes Virology 325 2004 287 296
12. I. Stephenson, K.G. Nicholson, R. Glück, R. Mischler, R.W. Newman, A.M. Palache, N.Q. Verlander, F. Warburton, J.M. Wood, and M.C. Zambon Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial Lancet 362 2003 1959 1966
13. W.W. Thompson, D.K. Shay, E. Weintraub, L. Brammer, N. Cox, L.J. Anderson, and K. Fukuda Mortality associated with influenza and respiratory syncytial virus in the United States JAMA 289 2003 179 186
14. J.J. Treanor, E.L. Tierney, S.L. Zebedee, R.A. Lamb, and B.R. Murphy Passively transferred monoclonal Ab to the M2 protein inhibits influenza A virus replication in mice J. Virol. 64 1990 1375 1377
15. R.G. Webster, W.J. Bean, O.T. Gorman, T.M. Chambers, and Y. Kawaoka Evolution and ecology of influenza A viruses Microbiol. Rev. 56 1992 152 179
16. I.A. Wilson, and N.J. Cox Structural basis of immune recognition of influenza virus hemagglutinin Annu. Rev. Immunol. 8 1990 737 771
17. P.F. Wright, and R.G. Webster Orthomyxoviruses D.M. Knipe Fields Virology 2001 Lippincott, Williams & Wilkens Philadelphia, PA 1533 1580